ArticleFamily practice2026
Assessing the risk of drug-induced corrected QT interval prolongation in primary care.
Article in Family practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTisdale risk score has been validated for predicting drug-induced QTc prolongation (QTP) in cardiac care. This study aims to determine whether it can guide prescribing and monitoring of QTc-prolonging medications in primary care.
methodsA retrospective chart audit using Tisdale Risk Score was conducted. Data from 486 primary care patients from two Family Medicine Clinics, prescribed medications with known or possible risk of Torsades de Pointes (TdP) were reviewed. Eighty-five patients with pre- and post-pharmacotherapy ECGs comprised the cases. A control group of 184 patients not on QTc-prolonging medications was assessed. Patients were categorized as low, moderate, or high risk for QTP.
resultsPsychotropics were the most frequently prescribed QTc-prolonging medications. Baseline QTc did not differ significantly between cases (428 ms) and controls (426 ms). Among cases, most were stratified as low risk (69.4%), with fewer in moderate (25.9%) and high-risk (4.7%) categories. Comparatively, 99.5% of control patients were at low risk. QTc prolongation occurred in 5/85 (5.9%) post-pharmacotherapy, with none in the high-risk category. Odds ratio for QTP in moderate-risk patients versus low-risk was 0.71 (95% CI: 0.07-6.98).
conclusionsMost primary care patients were at low risk for drug-induced QTc prolongation. QTP events were low with none in the high-risk category, which limited evaluation of association between risk categories and QTc prolongation. The study highlights commonly prescribed QTc-prolonging medications in family medicine and their variable QTc effects, emphasizing the need for an outpatient-tailored risk assessment tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.